{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:52:57Z","timestamp":1789537977337,"version":"build-2803163510"},"reference-count":8,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Perinatol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The objective of this study was to compare 60\u2009mg daily (QD) extended released (XR) nifedipine to 30\u2009mg twice daily (BID) for blood pressure (BP) control antepartum and postpartum.<\/jats:p><jats:p>This is a retrospective chart review conducted at the Mount Sinai Health System. Patients admitted from January 1, 2015, to April 30, 2021, diagnosed with a hypertensive disorder of pregnancy, who received nifedipine XR 30\u2009mg BID or 60\u2009mg QD for intrapartum or postpartum BP control were included. The primary outcome was the need for up-titration (i.e., the need for an increase in nifedipine dose or addition of another antihypertensive) after reaching one of the study doses (30\u2009mg BID or 60\u2009mg QD). Patients were excluded if they had preexisting renal disease or were already on oral antihypertensives. In a 1:1 ratio between single- and twice-daily dosing groups, the sample size needed to detect a 20% difference in up-titration rate to achieve 0.80 power is 97 patients per group, for a total of 194 patients. This is based on a Pearson chi-square test with a significance level of 0.05.<\/jats:p><jats:p>A total of 237 patients were included, 139 (59%) received 30\u2009mg BID and 98 (41%) 60\u2009mg QD. There was no statistically significant difference in the need for an increase in nifedipine dose or addition of another oral antihypertensive agent between those receiving 30\u2009mg BID versus 60\u2009mg QD (33.8 vs. 35.7%; adjusted odds ratio [aOR], 95% confidence interval [CI]: 0.90 [0.50\u20131.60]; p\u2009=\u20090.71). There was no difference in the need for emergency hypertensive treatment after reaching the study dose (p\u2009=\u20090.19) or readmission for BP control between groups (p\u2009&gt;\u20090.99).<\/jats:p><jats:p>These findings suggest that BID dosing does not confer better BP control in the antepartum or postpartum periods. Thus, daily dosing is reasonable and may be preferable for patient convenience and compliance.<\/jats:p>","DOI":"10.1055\/a-2486-8840","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:14:51Z","timestamp":1732666491000},"page":"1281-1287","source":"Crossref","is-referenced-by-count":1,"title":["Daily versus Twice Daily Nifedipine for Blood Pressure Control in Pregnancy and Postpartum"],"prefix":"10.1055","volume":"42","author":[{"given":"Jessica A.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9149-4015","authenticated-orcid":false,"given":"Isabelle C.","family":"Band","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Bianco","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"ACOG Practice Bulletin No. 222: Gestational hypertension and preeclampsia","volume":"135","author":"American College of Obstetricians and Gynecologists","year":"2020","journal-title":"Obstet Gynecol"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/AOG.0000000000003020","article-title":"ACOG Practice Bulletin No. 203: chronic hypertension in pregnancy","volume":"133","author":"American College of Obstetricians and Gynecologists' Committee on Practice Bulletins\u2014Obstetrics","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00003088-200948030-00002","article-title":"Effect of pregnancy on the pharmacokinetics of antihypertensive drugs","volume":"48","author":"G D Anderson","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1004010","DOI":"10.3389\/fphar.2022.1004010","article-title":"Impact of pregnancy related hormones on drug metabolizing enzyme and transport protein concentrations in human hepatocytes","volume":"13","author":"M M Fashe","year":"2022","journal-title":"Front Pharmacol"},{"issue":"06","key":"ref5","first-page":"e13","article-title":"ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"P K Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s00228-022-03382-3","article-title":"Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review","volume":"78","author":"D van de Vusse","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijcard.2016.04.082","article-title":"Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: a meta-regression analysis","volume":"216","author":"E R Weeda","year":"2016","journal-title":"Int J Cardiol"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/QAI.0000000000000501","article-title":"Effect of pregnancy and the postpartum period on adherence to antiretroviral therapy among HIV-infected women established on treatment","volume":"68","author":"C E Henegar","year":"2015","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["American Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2486-8840.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T22:31:39Z","timestamp":1751927499000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2486-8840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":8,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,7,7]]},"published-print":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2486-8840","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0735-1631","1098-8785"],"issn-type":[{"value":"0735-1631","type":"print"},{"value":"1098-8785","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11,26]]},"published":{"date-parts":[[2024,11,26]]}}}